By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

TiGenix 

Head Office
Technologielaan 3
Leuven    B - 3001  Belgium
Phone: 32-16-39-60-60 Fax: 32-16-39-60-70


SEARCH JOBS


Industry
Biotechnology






Company News
TiGenix Announces Cx601 Meets Primary Endpoint In Pivotal Phase III Trial 8/24/2015 8:54:10 AM
TiGenix Publishes Transparency Notification Pursuant To Article 14 Of The Law Of May 2, 2007 8/7/2015 12:19:49 PM
TiGenix Obtains FDA's Endorsement Through Special Protocol Assessment For Its Cx601 Phase III Registration Trial In The US 8/7/2015 8:48:58 AM
TiGenix: Transparency Information 7/31/2015 12:38:10 PM
Dirk Büscher And José Terencio Resign From TiGenix Board Of Directors 7/31/2015 11:22:58 AM
TiGenix Snaps Up Coretherapix In Deal Worth $318.5 Million 7/30/2015 12:30:28 PM
TiGenix: Notice In Relation To The Convertible Bonds Due 2018 7/6/2015 9:31:54 AM
TiGenix Starts Cx601 Marketing Authorization Application Process 6/11/2015 8:52:28 AM
TiGenix Release: Safety And Tolerability Of Cx611 Confirmed In Phase I Sepsis Challenge Trial 5/28/2015 8:48:27 AM
TiGenix: Convening Notice To The Extraordinary Shareholders' Meeting To Be Held On 2 June 2015 5/13/2015 9:48:13 AM
123456789
//-->